Net Loss Per Share of Common Stock

12 Months Ended

Dec. 31, 2018

Net Loss Per Share of Common Stock

Net Loss Per Share of Common Stock

5. Net Loss Per Share of Common Stock

The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2018 and 2017:

	Year ended December 31,
	2018		2017
Basic and diluted net loss per share of common stock:
Net loss attributable to Onconova Therapeutics, Inc	$	(20,573,000)	$	(24,092,000)
Weighted average shares of common stock outstanding		4,124,073		600,022
Net loss per share of common stock—basic and diluted	$	(4.99)	$	(40.15)

The following potentially dilutive securities outstanding at December 31, 2018 and 2017 have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive (reflects the number of common shares as if the dilutive securities had been converted to common stock):

	December 31,
	2018	2017
Warrants	5,725,506	3,294,771
Stock options	379,328	894,996
	6,104,834	4,189,767